Acadia Pharmaceuticals Inc.
ACADStock
$25.63+16.45%52W
Market Cap$4.47B
P/E11.42x
Div yield—
Beta0.86
Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-14.06%
Price vs S&P 500 (4W)20.27%
VGM Score51.67
Market Capitalization$4.47B
P/E Ratio (Annual)11.42x
Earnings Surprise History
Q1 260.02est. 0.06
Analyst Recommendations
Apr 2026
May 2026
Jun 2026
Jul 2026
4.00
4.00
4.00
4.00
Industry Peers — Pharmaceuticals(563)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
ACADAcadia Pharmaceuticals Inc. | C | C | B | $25.63 |
| LLYEli Lilly & Co. | D | B | B | $1169.17 |
| JNJJohnson & Johnson | D | C | B | $249.97 |
| ABBVABBVIE INC. | D | C | B | $254.39 |
| MRKMerck & Co., Inc. | C | C | B | $127.63 |
| NVSNovartis AG | C | C | C | $152.73 |
| NVONovo-Nordisk A/S | C | B | C | $51.48 |
| AZNAstraZeneca PLC | C | B | C | $169.29 |
| ABTAbbott Laboratories | C | C | D | $98.83 |
| PFEPfizer Inc. | B | C | C | $25.14 |
| VRTXVertex Pharmaceuticals Inc | D | C | C | $486.03 |
About
Acadia Pharmaceuticals is a biopharmaceutical company with two core franchises in neurological and rare diseases. Its neurological franchise is anchored by NUPLAZID (pimavanserin), the first FDA-approved treatment for Parkinson's disease psychosis, while its rare disease franchise is built on DAYBUE, the first FDA-approved treatment for Rett syndrome. The company's clinical pipeline includes programs targeting Alzheimer's disease psychosis, Lewy Body Dementia psychosis, and other neurological disorders.